Amylyx Pharmaceuticals (AMLX) Other Operating Expenses (2022 - 2024)

Amylyx Pharmaceuticals' Other Operating Expenses history runs 3 years deep, the most recent figure standing at $37.0 million for Q3 2024.

• In Q3 2024, Other Operating Expenses rose 609.31% year-over-year to $37.0 million; the TTM figure through Jun 2025 stood at $37.0 million (down 73.26% YoY), while the FY2024 annual figure was $160.8 million, up 532.19% from the prior year.
• Other Operating Expenses was $37.0 million for Q3 2024 at Amylyx Pharmaceuticals, up from $7.4 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $116.4 million in Q1 2024 to a low of $172000.0 in Q3 2022.
• Historically, Other Operating Expenses has averaged $21.0 million across 3 years, with a median of $5.6 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Other Operating Expenses soared 2933.72% in 2023, then surged 32.94% in 2024.
• A 3-year view of Other Operating Expenses shows it stood at $2.8 million in 2022, then soared by 231.8% to $9.4 million in 2023, then soared by 295.43% to $37.0 million in 2024.
• The last three Other Operating Expenses figures came in at $37.0 million (Q3 2024), $7.4 million (Q2 2024), and $116.4 million (Q1 2024), per Business Quant data.